Takeda Pharmaceutical (TAK) Accounts Payables (2017 - 2026)

Takeda Pharmaceutical's Accounts Payables history runs 10 years deep, the most recent figure standing at $3.1 billion for Q1 2026.

• On a quarterly basis, Accounts Payables rose 0.52% year-over-year to $3.1 billion in Q1 2026; TTM through Mar 2026 was $3.1 billion, a 0.52% increase from a year earlier, with the FY2026 full-year figure at $3.3 billion, up 4.56% from the prior year.
• Accounts Payables climbed to $3.1 billion in Q1 2026 per TAK's latest filing, from $3.0 billion in the prior quarter.
• Across five years, Accounts Payables topped out at $4.9 billion in Q1 2023 and bottomed at $2.7 billion in Q4 2022.
• The 5-year median for Accounts Payables is $3.0 billion (2025), against an average of $3.2 billion.
• Across the five-year window, Accounts Payables jumped 36.76% in 2022 and slipped 24.73% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $2.7 billion in 2022, then advanced by 21.3% to $3.3 billion in 2023, then dropped by 7.49% to $3.0 billion in 2024, then advanced by 0.38% to $3.0 billion in 2025, then grew by 3.12% to $3.1 billion in 2026.
• Per Business Quant, the three latest TAK Accounts Payables figures stand at $3.1 billion (Q1 2026), $3.0 billion (Q4 2025), and $3.0 billion (Q3 2025).